Page last updated: 2024-08-26

bosentan anhydrous and Cardiac Septal Defect

bosentan anhydrous has been researched along with Cardiac Septal Defect in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
He, F; Ren, R; Xiao, X1
Schulze-Neick, I1

Other Studies

2 other study(ies) available for bosentan anhydrous and Cardiac Septal Defect

ArticleYear
Bosentan treatment for pulmonary arterial hypertension due to complete atrioventricular septal defect in an infant with Down's syndrome.
    International journal of cardiology, 2014, Dec-20, Volume: 177, Issue:3

    Topics: Antihypertensive Agents; Bosentan; Down Syndrome; Heart Septal Defects; Humans; Hypertension, Pulmonary; Infant; Male; Mitral Valve Insufficiency; Sulfonamides; Treatment Outcome; Ultrasonography

2014
[PAH in congenital heart defects--therapeutic experiences with children and adults].
    Kinderkrankenschwester : Organ der Sektion Kinderkrankenpflege, 2005, Volume: 24, Issue:6

    Topics: Antihypertensive Agents; Bosentan; Child; Clinical Trials as Topic; Endothelin Receptor Antagonists; Heart Defects, Congenital; Heart Septal Defects; Humans; Hypertension, Pulmonary; Sulfonamides; Treatment Outcome; Vascular Resistance

2005